MUC5AC and MUC5B Levels in COPD Patients
Author Information
Author(s): Pincikova Terezia, Merikallio Heta, Kotortsi Ioanna, Karimi Reza, Li Chuan-Xing, Lappi-Blanco Elisa, Lindén Sara K., Padra Médea, Wheelock Åsa M., Nyrén Sven, Sköld Carl Magnus, Kaarteenaho Riitta L.
Primary Institution: Karolinska Institute
Hypothesis
The immunohistochemical expression of MUC5AC and MUC5B in human large airways would differ among never-smokers, smokers, and COPD patients and may be related to lung function impairment and the progression of chronic airflow limitation over time.
Conclusion
High MUC5AC expression and low MUC5B expression in goblet cells are associated with smoking exposure and the progression of chronic airflow limitation in COPD.
Supporting Evidence
- Smokers had higher MUC5AC and lower MUC5B expression compared to never-smokers.
- MUC5B expression correlated positively with lung function measures.
- Chronic bronchitis and emphysema were associated with higher MUC5AC and lower MUC5B expression.
- Progression of chronic airflow limitation correlated with MUC5B expression.
- Smoking history correlated positively with MUC5AC expression and negatively with MUC5B expression.
Takeaway
This study found that two types of mucus proteins, MUC5AC and MUC5B, behave differently in smokers and COPD patients, which might help us understand lung disease better.
Methodology
Bronchial mucosal biopsies and bronchial wash samples were collected from patients and analyzed for MUC5AC and MUC5B expression using immunohistochemistry.
Limitations
The study had a lower number of participants in the follow-up study and many biopsies lacked submucosal gland areas.
Participant Demographics
Participants included healthy never-smokers, smokers with normal lung function, and COPD patients, matched for age, sex, and smoking history.
Statistical Information
P-Value
0.018
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website